Vertex Pharma Doubles Cystic Fibrosis Research Facility

June 20, 2018  Source: Fierce Biotech 549

Boston-based Vertex Pharmaceuticals has more than doubled their research facility in San Diego where they first discovered their key Cystic Fibrosis Drug adding more than 90000 sq ft. to it. The total facility will be now 170,000 sq. ft improving the pharma giant's capability to achieve the next generation of blockbusters.

In 2015 Vertex aimed to expand the earlier 80,000 sq. ft facility slowly by added 70 staff members to its 180 employee team and was focusing to complete construction in the second half of 2017. Now, the company has conventionally started the new laboratory.

A total of 70 percent of the new space will be used for research and development and another 4,000 sq. ft will serve as an incubator for external collaboration, clearly portraying Vertex’s aims at delving into the San Diego biotech scene to support its R&D plans.

Vertex CSO David Altshuler, M.D., Ph.D., said in a statement. “Our San Diego researchers have worked for the last 20 years doing what was once thought to be impossible, advancing the first medicines that treat the latent of cystic fibrosis, This team is a censorious part of our global research attempt, and the new site will allow us to continue investing in new studies to bring more transformative medicines to the patients with grave diseases.”

By Ddu
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.